SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Ganga Pharmaceuticals Ltd

BSE: 539680 NSE: ISIN: INE615T01017
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Ganga Pharmaceuticals Ltd belong to?
Ganga Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Ganga Pharmaceuticals Ltd a good quality company?
Ganga Pharmaceuticals Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Ganga Pharmaceuticals Ltd undervalued or overvalued?
Ganga Pharmaceuticals Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Ganga Pharmaceuticals Ltd a good buy now?
Ganga Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd revenue growth is -3.7% for FY-2025 , which is below its 5 year CAGR of -3% , indicating slower growth.
Q.2 Gross Profit margin of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 5.4% for FY-2025 , which is above its 5 year median of 4.2% , indicating increasing margins.
Q.3 Operating Profit Margin of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -4.41% for FY-2025 , which is below its 5 year median of 1.39% indicating decreasing margins.
Q.4 Net Profit Margin of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Net Profit Margin is 3% for FY-2025 , is above with its 5 year median of 1.52%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 5.4 4.2
Operating Profit Margin -4.41 1.39
Net Profit Margin 3 1.52
Q.5 Return on Asset of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Return on Asset is 0.9%, which is above its 5 year historical median of 0.49%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Return on equity is 1.22% for FY-2025 , which is above its historical median of 0.72%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Return on capital employed is 3.22% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Cash conversion cycle is 264 days, above its historical median of 229 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.3 0.32
ROE 1.22 0.72
ROCE 3.22 3.36
Cash Conversion Cycle 264 days 229 days
Q.9 Debt to Equity ratio of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Debt-to-Equity ratio is 0.22 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd Debt to cash flow from operations is -2.46 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Ganga Pharmaceuticals Ltd?
Promoters hold 50.91% of the Ganga Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Ganga Pharmaceuticals Ltd vs industry peers?
Ganga Pharmaceuticals Ltd revenue CAGR is -3.04% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 2.6 137.1
Gross Profit 0.1 15.1
Operating Profit -0.1 16
Net Profit 0.1 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.3 0.8
ROE 1.22 8.91
ROCE 3.22 11.59
Cash Conversion Cycle (days) 264.38 76

Valuation & price assessment

Q.1 Stock return of Ganga Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -0.9% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -0.9% 9.9% -4.9% 7.3%
Q.3 Valuation ratios of Ganga Pharmaceuticals Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 89.76 108.85 40.28
Price to Book 0.88 0.81 2.77
Price to Sales 2.69 1.69 2.65
EV to EBITDA 25.69 20.60 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×